Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Not yet recruiting1
Completed1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting133%
completed133%
enrolling_by_invitation133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationphase_3

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

NCT04762992
not_yet_recruitingnot_applicable

Low-Dose Enoxaparin in Psoriasis

NCT06416566
completedphase_2

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871

Clinical Trials (3)

Showing 3 of 3 trials
NCT04762992Phase 3

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

Enrolling By Invitation
NCT06416566Not Applicable

Low-Dose Enoxaparin in Psoriasis

Not Yet Recruiting
NCT02366871Phase 2

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3